Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient Enrollments

Loading news article.

Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient Enrollments | WAPE

Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient Enrollments

Article summary

Related companies

Comments —